Literature DB >> 1690177

Secretion of interleukin-6 (IL-6) by human monocytes stimulated by muramyl dipeptide and tumour necrosis factor alpha.

J Sancéau1, R Falcoff, F Beranger, D B Carter, J Wietzerbin.   

Abstract

We studied IL-6 gene expression in human monocytes stimulated by muramyl dipeptide (MDP), a synthetic immunomodulator derived from mycobacterial cell walls. In control monocytes, two IL-6 transcripts of 3.4 kb and 1.6 kb were easily detected at 2.5 hr of culture and remained stable until 18 hr. In MDP-treated monocytes, three IL-6 RNA species displayed different kinetics of accumulation: a 3.4 kb RNA whose expression already reached its maximum after 2.5 hr exposure to MDP; a 1.6 kb RNA whose expression peaked at 5 hr; and a new RNA species of 1.4 kb which was transiently induced in early time of cell stimulation. TNF-alpha co-operated with MDP to increase IL-6 gene expression and secretion of biological active protein (measured by the hybridoma plasmacytoma growth factor assay). MDP exhibits a broad spectrum of immunomodulation properties such as adjuvant activity, enhancement of macrophage cytotoxicity against tumour and induction of non-specific resistance to intracellular agents. The results reported here suggest that these properties might be linked to the stimulation by MDP of genes coding for key cytokines such as IL-6, TNF and IL-1.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1690177      PMCID: PMC1385719     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  24 in total

1.  Differential mRNA responses in human macrophages activated by interferon-gamma and muramyl dipeptide.

Authors:  M W Vermeulen; J R David; H G Remold
Journal:  J Immunol       Date:  1987-07-01       Impact factor: 5.422

2.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.

Authors:  J Gauldie; C Richards; D Harnish; P Lansdorp; H Baumann
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

3.  Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives.

Authors:  F Ellouz; A Adam; R Ciorbaru; E Lederer
Journal:  Biochem Biophys Res Commun       Date:  1974-08-19       Impact factor: 3.575

4.  Molecular cloning and expression of hybridoma growth factor in Escherichia coli.

Authors:  J P Brakenhoff; E R de Groot; R F Evers; H Pannekoek; L A Aarden
Journal:  J Immunol       Date:  1987-12-15       Impact factor: 5.422

5.  Interferon-beta 2 (BSF-2) mRNA is expressed in human monocytes.

Authors:  J Sancéau; R Falcoff; A Zilberstein; F Béranger; J Lebeau; M Revel; C Vaquero
Journal:  J Interferon Res       Date:  1988-08

6.  Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2).

Authors:  T Hirano; T Taga; N Nakano; K Yasukawa; S Kashiwamura; K Shimizu; K Nakajima; K H Pyun; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

7.  Induction of a 26-kDa-protein mRNA in human cells treated with an interleukin-1-related, leukocyte-derived factor.

Authors:  J Content; L De Wit; P Poupart; G Opdenakker; J Van Damme; A Billiau
Journal:  Eur J Biochem       Date:  1985-10-15

8.  Induction of beta 2-interferon by tumor necrosis factor: a homeostatic mechanism in the control of cell proliferation.

Authors:  M Kohase; D Henriksen-DeStefano; L T May; J Vilcek; P B Sehgal
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

9.  Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas.

Authors:  J Van Snick; S Cayphas; A Vink; C Uyttenhove; P G Coulie; M R Rubira; R J Simpson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

10.  Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines.

Authors:  A Zilberstein; R Ruggieri; J H Korn; M Revel
Journal:  EMBO J       Date:  1986-10       Impact factor: 11.598

View more
  7 in total

Review 1.  The quest for better understanding of HLA-disease association: scenes from a road less travelled by.

Authors:  Joseph Holoshitz
Journal:  Discov Med       Date:  2013-09       Impact factor: 2.970

2.  Modulatory effect of mycobacterium cell wall extract (Regressin) on lymphocyte blastogenic activity and macrophage cytokine gene transcription in swine.

Authors:  S A Vézina; D Archambault
Journal:  Clin Diagn Lab Immunol       Date:  1997-05

3.  Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.

Authors:  E C De Boer; W H De Jong; P A Steerenberg; L A Aarden; E Tetteroo; E R De Groot; A P Van der Meijden; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  Effect of proinflammatory cytokines on the human MUC5AC promoter activity in vitro and in vivo.

Authors:  I-Jong Wang; Chun-Yin Wu; Fung-Rong Hu
Journal:  Clin Ophthalmol       Date:  2007-03

5.  Characterization of Early-Onset Finger Osteoarthritis-Like Condition Using Patient-Derived Induced Pluripotent Stem Cells.

Authors:  Yeri Alice Rim; Yoojun Nam; Narae Park; Kijun Lee; Hyerin Jung; Seung Min Jung; Jennifer Lee; Ji Hyeon Ju
Journal:  Cells       Date:  2021-02-04       Impact factor: 6.600

Review 6.  TNF-α in Uveitis: From Bench to Clinic.

Authors:  Qi Jiang; Zhaohuai Li; Tianyu Tao; Runping Duan; Xianggui Wang; Wenru Su
Journal:  Front Pharmacol       Date:  2021-11-02       Impact factor: 5.810

Review 7.  Forensic biomarkers of lethal traumatic brain injury.

Authors:  Johann Zwirner; Rachel Kulakofsky; Antonia Fitzek; Ann Sophie Schröder; Simone Bohnert; Heike Franke; Thomas Renné; Rexson Tse; Benjamin Ondruschka
Journal:  Int J Legal Med       Date:  2022-02-28       Impact factor: 2.791

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.